First Midwest Bank Trust Division cut its position in Bristol-Myers Squibb Co (NYSE:BMY) by 7.1% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 24,735 shares of the biopharmaceutical company’s stock after selling 1,899 shares during the quarter. First Midwest Bank Trust Division’s holdings in Bristol-Myers Squibb were worth $1,122,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds have also recently made changes to their positions in the company. FMR LLC raised its holdings in shares of Bristol-Myers Squibb by 313.9% during the first quarter. FMR LLC now owns 40,851,887 shares of the biopharmaceutical company’s stock worth $1,949,043,000 after purchasing an additional 30,981,844 shares during the period. Norges Bank bought a new position in shares of Bristol-Myers Squibb during the fourth quarter worth about $797,038,000. Janus Henderson Group PLC grew its position in shares of Bristol-Myers Squibb by 15.5% during the first quarter. Janus Henderson Group PLC now owns 9,196,512 shares of the biopharmaceutical company’s stock worth $438,767,000 after acquiring an additional 1,231,639 shares during the last quarter. Legal & General Group Plc grew its position in shares of Bristol-Myers Squibb by 5.9% during the fourth quarter. Legal & General Group Plc now owns 8,568,445 shares of the biopharmaceutical company’s stock worth $445,300,000 after acquiring an additional 474,820 shares during the last quarter. Finally, Nordea Investment Management AB grew its position in shares of Bristol-Myers Squibb by 380.2% during the first quarter. Nordea Investment Management AB now owns 6,252,847 shares of the biopharmaceutical company’s stock worth $298,324,000 after acquiring an additional 4,950,748 shares during the last quarter. Institutional investors and hedge funds own 77.60% of the company’s stock.
In other news, insider Karen Murphy Santiago sold 3,065 shares of the firm’s stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $47.56, for a total transaction of $145,771.40. Following the completion of the transaction, the insider now owns 3,066 shares in the company, valued at approximately $145,818.96. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Theodore R. Samuels II acquired 5,000 shares of Bristol-Myers Squibb stock in a transaction dated Thursday, May 16th. The shares were acquired at an average price of $47.29 per share, with a total value of $236,450.00. Following the transaction, the director now owns 27,000 shares in the company, valued at approximately $1,276,830. The disclosure for this purchase can be found here. Company insiders own 0.13% of the company’s stock.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, July 25th. The biopharmaceutical company reported $1.18 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.06 by $0.12. Bristol-Myers Squibb had a net margin of 26.14% and a return on equity of 47.63%. The company had revenue of $6.27 billion during the quarter, compared to analyst estimates of $6.10 billion. During the same quarter last year, the firm posted $1.01 EPS. The business’s revenue for the quarter was up 10.0% on a year-over-year basis. Sell-side analysts forecast that Bristol-Myers Squibb Co will post 4.26 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, August 1st. Stockholders of record on Friday, July 5th will be given a dividend of $0.41 per share. The ex-dividend date is Wednesday, July 3rd. This represents a $1.64 annualized dividend and a dividend yield of 3.65%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 41.21%.
Several equities analysts have recently commented on BMY shares. BMO Capital Markets started coverage on shares of Yelp in a research report on Wednesday, April 17th. They set an “outperform” rating for the company. Argus lowered shares of Clorox from a “buy” rating to a “hold” rating in a research report on Monday, May 20th. Zacks Investment Research lowered shares of GENEL ENERGY PL/ADR from a “buy” rating to a “hold” rating in a research report on Tuesday, May 7th. ValuEngine lowered shares of Zumiez from a “hold” rating to a “sell” rating in a research report on Tuesday, July 2nd. Finally, Goldman Sachs Group set a $27.00 price target on shares of Melco Resorts & Entertainment and gave the stock a “buy” rating in a research report on Tuesday, May 28th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and nine have issued a buy rating to the company’s stock. Bristol-Myers Squibb has a consensus rating of “Hold” and an average price target of $56.22.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Featured Story: Balance Sheet
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.